Programmed cell death (PCD) has been a major area of constantly growing interest over the last three decades. Originally, apoptosis was considered the only mechanistic pathway for PCD, but recently several different pathways (i.e., necroptosis, pyroptosis, ferroptosis) have emerged as important in both normal and pathological conditions. This review focuses on programmed cell necrosis (i.e., necroptosis) as a promising research direction that will help us in understanding the molecular and cellular processes behind different pathological conditions, such as chronic inflammation, neurodegeneration, and cardiovascular diseases. In addition, we discuss natural and chemical compounds and novel targeted therapies triggering necroptosis to induce cell death in cancer cells to overcome chemoresistance.
Bibliographical noteFunding Information:
This work was supported in part by the Michigan Ovarian Cancer Alliance (MIOCA) , the Liz Tilberis early career OCRA award, the Marsha Rivkin Ovarian Center pilot award , the Elsa U. Pardee foundation , and the WeRoc research grant from Foundation for Women's Cancer (to I.C.)
© 2020 Elsevier Inc.
- Cardiovascular disorders
- Cell death
- Cell programmed necrosis
- Neurodegenerative diseases
PubMed: MeSH publication types
- Journal Article
- Research Support, Non-U.S. Gov't